Trastuzumab Cardiotoxicity

Medication

Baseline Risk Assessment

Risk Factors

What Would You Advise Regarding the Her2 Targeted Therapy in this Patient

Maximize Cardioprotective Therapy

Cardioprotective Therapy

Restarting Trastuzumab after Toxicity

New Drugs Approved for the Treatment of Metastatic Breast Cancer

Pyrotinium

Welcome

What are the 3 most important take-home messages for our readers?

What are MPNs?

Importance of Cardiovascular Disease in MPNs

Overlap in Pathophysiology

What are the main pathways responsible for the development of cardiovascular disease in MPN?

What is the significance of the JAK-STAT pathway in MPNs?

Lesser-known pathways in MPNs

What are the most exciting advances in our understanding of MPNs and mitigating cardiovascular disease risk?

Intro

What are the 3 most important take-home messages?

Heterogeneity Between Studies

Closing Thoughts

What do you think are the greatest knowledge gaps as it relates to cardioprotection in cancer patients and survivors?

What are the remaining knowledge gaps?

Where Does the Science Need to Go?

PRADATU Study

Closing Remarks

When Should One Suspect all Amylosis from the Cardiologists

When Should the Oncologist Suspect Ale Amyloidosis

What Should Be the Trigger Signs

Specifically Suspect Cardiac Involvement

The Workup

The Greatest Needs in the Field of Amylosis

Diagnosis

Approved Treatment for Cardiac Amyloidosis

A Definitive Imaging Based Diagnosis for Al Amyloidosis

Rates of Transplants for Amyloidosis

Pre-Lecture Questions

Agents that may cause heart failure

Who is at increased risk of developing cardiotoxicity?

The earlier the treatment, the better?

HER2 antagonists

What about patients who have normal heart function?

Other vascular toxicities

CTLA4 inhibitors

What is the likelihood of missing a tumor?

Q&A

Top 10 Causes of Death in the US

Innovative Compounds in Phase I-III Development

Survival of Patients with Cancer & CVD

Implications of Cardiac Toxicity in Cancer Patients

Integrated Approach of CVD & Cancer

Anthracycline Cardiotoxicity Risk

Is Anthracycline Cardiotoxicity Reversible or Not?

Time-to-Toxicity is Key

ICI-Myocarditis Treatment

Prostate Cancer & CVD Summary

Intro

Late gadolinium enhancement (LGE)

When does cardiotoxicity present?

What about long-term risk?

Test Characteristics

What is the pattern of LGE?

Predictors of cardiotoxicity

Risk Factor Modification

What are alkylating agents?

Next week's speakers

Intro

Anti-HER2 therapy

How does cardio-oncology work with the breast cancer team?

What do you offer the patient?

How do you create realistic expectations for patients?

Why is cardio-oncology important for breast cancer survivors?

What is the importance of knowing your numbers?

What are your plans for the future?

What is an ongoing clinical trial for patients with HER2-positive breast cancer?

Closing remarks

Esc Guidelines on Cardio Oncology

What Are the Determinants of Heart Failure Cancer

Risk Factors

Long-Term Follow-Up after the Completion of Cancer Therapy

Modifiable Risk Factors

First Blood Count

Newly Diagnosed Cardiovascular Disease

Cancer Treatments

Cardiac Involvement of Cancer

Reduce the Risk of Cardiotoxicity

Agenda

Risk stratification

Topoisomerase 2A and 2B

Anthracycline cardiotoxicity

PD-1 ligand inhibitors

CAR-T cells

Can BNP protect future heart failure?

What do we do with these findings?

What are the recent trials in cancer patients?

How are we doing in Cardiology?

Welcome

Key messages of the guidelines

What is the importance of a baseline assessment?

Management of trastuzumab-induced cardiac dysfunction

Long-term cardiovascular surveillance

Question time

Is it possible to have an abnormal LV strain in oncology patients who have no other cardiovascular risk factors?

What is the importance of a baseline risk assessment?

Should we be doing specialized cardiovascular safety RCTs with oncology drugs?

How should we organize the cardiovascular follow-up of cancer survivors?

Open Heart Surgery

What Cardio Oncology Entails

Cardiac Dysfunction

Secondary Prevention

Imaging

Longitudinal Strain

Questions and Answers

Immunotherapies versus Traditional Chemotherapy versus Radiation

Intermediate Risk

How Do You Get a 3d Echo